Bionoid Pharma Inc. Logo

Bionoid Pharma Inc.

BINP

(0.0)
Stock Price

0,20 USD

-37.82% ROA

33.29% ROE

-507.7x PER

Market Cap.

12.188.975,00 USD

-175.99% DER

0% Yield

-137.58% NPM

Bionoid Pharma Inc. Stock Analysis

Bionoid Pharma Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bionoid Pharma Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Bionoid Pharma Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bionoid Pharma Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

Bionoid Pharma Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bionoid Pharma Inc. Revenue
Year Revenue Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2013 92 100%
2019 56.172 99.84%
2020 30.657 -83.23%
2021 102.120 69.98%
2022 36.041 -183.34%
2023 37.506 3.91%
2024 20.568 -82.35%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bionoid Pharma Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2006 212.060
2007 151.217 -40.24%
2008 134.327 -12.57%
2009 134.504 0.13%
2010 483.592 72.19%
2011 602.842 19.78%
2013 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bionoid Pharma Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 0
2007 0 0%
2008 0 0%
2009 2.793.779 100%
2010 3.148.797 11.27%
2011 0 0%
2013 366 100%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bionoid Pharma Inc. EBITDA
Year EBITDA Growth
2006 -1.552.848
2007 -589.419 -163.45%
2008 -1.175.035 49.84%
2009 -2.888.455 59.32%
2010 -3.850.952 24.99%
2011 -5.128.910 24.92%
2013 -386 -1332084.42%
2019 39.480 100.98%
2020 -29.480 233.92%
2021 -76.830 61.63%
2022 4.860 1680.86%
2023 -4.320 212.5%
2024 3.040 242.11%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bionoid Pharma Inc. Gross Profit
Year Gross Profit Growth
2006 0
2007 0 0%
2008 -43.827 100%
2009 -181.500 75.85%
2010 -252.457 28.11%
2011 -7.644 -3202.68%
2013 47 16363.83%
2019 56.172 99.92%
2020 14.072 -299.18%
2021 46.010 69.42%
2022 17.348 -165.22%
2023 8.417 -106.11%
2024 7.680 -9.6%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bionoid Pharma Inc. Net Profit
Year Net Profit Growth
2006 -2.077.147
2007 -1.263.489 -64.4%
2008 -1.589.500 20.51%
2009 -3.413.454 53.43%
2010 -3.908.668 12.67%
2011 -5.141.789 23.98%
2013 -1.623 -316903.02%
2019 27.148 105.97%
2020 -455.783 105.96%
2021 -135.258 -236.97%
2022 1.478 9251.42%
2023 -7.805 118.94%
2024 -14.292 45.39%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bionoid Pharma Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 -335 100%
2013 -46 -628.26%
2019 1 0%
2020 -12 100%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bionoid Pharma Inc. Free Cashflow
Year Free Cashflow Growth
2006 -715.102
2007 -531.074 -34.65%
2008 -373.470 -42.2%
2009 -485.599 23.09%
2010 -1.744.965 72.17%
2011 -818.079 -113.3%
2013 -358 -229053.78%
2019 67.401 100.53%
2020 -46.553 244.78%
2021 -19.257 -141.75%
2022 -20.645 6.72%
2023 230 9076.09%
2024 613 62.48%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bionoid Pharma Inc. Operating Cashflow
Year Operating Cashflow Growth
2006 -711.744
2007 -530.510 -34.16%
2008 -368.956 -43.79%
2009 -483.732 23.73%
2010 -1.734.290 72.11%
2011 -808.554 -114.49%
2013 -358 -226385.71%
2019 67.401 100.53%
2020 -46.553 244.78%
2021 -19.257 -141.75%
2022 -20.645 6.72%
2023 230 9076.09%
2024 613 62.48%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bionoid Pharma Inc. Capital Expenditure
Year Capital Expenditure Growth
2006 3.358
2007 564 -495.39%
2008 4.514 87.51%
2009 1.867 -141.78%
2010 10.675 82.51%
2011 9.525 -12.07%
2013 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bionoid Pharma Inc. Equity
Year Equity Growth
2006 -149.390
2007 -914.260 83.66%
2008 -1.521.722 39.92%
2009 -1.419.436 -7.21%
2010 -870.899 -62.99%
2011 -947.661 8.1%
2013 -1.144 -82809.97%
2019 414.982 100.28%
2020 -40.902 1114.58%
2021 -77.708 47.36%
2022 -76.230 -1.94%
2023 -84.035 9.29%
2024 -88.005 4.51%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bionoid Pharma Inc. Assets
Year Assets Growth
2006 459.041
2007 441.549 -3.96%
2008 399.639 -10.49%
2009 471.969 15.33%
2010 1.330.059 64.52%
2011 301.877 -340.6%
2013 138 -220248.18%
2019 529.619 99.97%
2020 123.735 -328.03%
2021 84.325 -46.74%
2022 83.146 -1.42%
2023 70.843 -17.37%
2024 70.310 -0.76%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bionoid Pharma Inc. Liabilities
Year Liabilities Growth
2006 608.431
2007 1.355.809 55.12%
2008 1.921.361 29.43%
2009 1.891.405 -1.58%
2010 2.200.958 14.06%
2011 1.249.538 -76.14%
2013 1.282 -97443.95%
2019 114.637 98.88%
2020 164.637 30.37%
2021 162.033 -1.61%
2022 159.376 -1.67%
2023 154.879 -2.9%
2024 158.315 2.17%

Bionoid Pharma Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-507.7x
Price To Sales Ratio
630.7x
POCF Ratio
-29667.37
PFCF Ratio
-26788.96
Price to Book Ratio
-153.39
EV to Sales
638.57
EV Over EBITDA
-628.69
EV to Operating CashFlow
-27123.27
EV to FreeCashFlow
-27123.27
Earnings Yield
-0
FreeCashFlow Yield
-0
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.02
ROE
0.33
Return On Assets
-0.38
Return On Capital Employed
0.26
Net Income per EBT
1
EBT Per Ebit
1.17
Ebit per Revenue
-1.17
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.39
Operating Profit Margin
-1.17
Pretax Profit Margin
-1.38
Net Profit Margin
-1.38

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.34
Return on Tangible Assets
-0.38
Days Sales Outstanding
0
Days Payables Outstanding
46.58
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
7.84
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
-0
Shareholders Equity per Share
-0
Interest Debt per Share
0
Debt to Equity
-1.76
Debt to Assets
2.2
Net Debt to EBITDA
-7.75
Current Ratio
0.34
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-101690
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bionoid Pharma Inc. Dividends
Year Dividends Growth

Bionoid Pharma Inc. Profile

About Bionoid Pharma Inc.

Bionoid Pharma Inc. engages in the hemp cultivation business. The company is based in Beverly Hills, California.

CEO
Ms. Patricia Colvin
Employee
5
Address
433 North Camden
Beverly Hills, 90210

Bionoid Pharma Inc. Executives & BODs

Bionoid Pharma Inc. Executives & BODs
# Name Age
1 Ms. Patricia Colvin
Director of Operations & Financial Controller
70

Bionoid Pharma Inc. Competitors